EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials

Michael W Weiner iD, Shaveta Kanoria, Melanie J Miller, Paul S Aisen, Laurel A Beckett, Catherine Conti, Adam Diaz, Derek Flenniken, Robert C Green, Danielle J Harvey, Clifford R Jack, William Jagust und 14 weitere

Alzheimer's & Dementia · 2025-01 · 21 (1)

DOI: 10.1002/alz.14321 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 22.12.2024. Verfasst von Michael W Weiner und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroimaging, Clinical Trials as Topic. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in standardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests. Additionally, ADNI provided data for the trials of the FDA‐approved treatments aducanumab, lecanemab, and donanemab. More than 6000 scientific papers have been published using ADNI data, reflecting ADNI's promotion of open science and data sharing. Despite its enormous success, ADNI has some limitations, particularly in generalizing its data and findings to the entire US/Canadian population. This introduction provides a historical overview of ADNI and highlights its significant accomplishments and future vision to pioneer “the clinical trial of the future” focusing on demographic inclusivity. Highlights The Alzheimer's Disease Neuroimaging Initiative (ADNI) introduced a novel model for public‐private partnerships and data sharing. It successfully validated amyloid and Tau PET imaging, as well as CSF and plasma biomarkers, for diagnosing Alzheimer's disease. ADNI generated and disseminated vital data for designing AD clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeuroimagingClinical Trials as TopicHumansBiomarkersPositron-Emission TomographyAmyloid beta-Peptidestau ProteinsUnited States

Stichwörter der Autor:innen

Alzheimer's Disease Neuroimaging InitiativeAlzheimer's diseaseAlzheimer's disease biomarkersAlzheimer's disease clinical trialsAlzheimer's disease progressionLaboratory of Neuro Imagingamyloidmagnetic resonance imagingneurodegenerationpositron emission tomographypost‐traumatic stress disordertauunderrepresented populations

Substanzen

BiomarkersAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
  • Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.
  • Department of Neurology, University of California San Francisco, San Francisco, California, USA.
  • Northern California Institute for Research and Education (NCIRE), San Francisco, California, USA.

ORCID-Profile: Michael W Weiner

Förderung

  • NIA NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute on Aging

Zitieren

APA

Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W., Lee, E. B., Morris, J. C., Nho, K., Nosheny, R., Okonkwo, O. C., Perrin, R. J., Petersen, R. C., …, & Alzheimer's Disease Neuroimaging Initiative (2025). Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimer's & Dementia, 21(1). https://doi.org/10.1002/alz.14321

Vancouver

Weiner MW, Kanoria S, Miller MJ, Aisen PS, Beckett LA, Conti C, et al. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimer's & Dementia. 2025;21(1). doi:10.1002/alz.14321

BibTeX
@article{Weiner2025,
  author = {Weiner, Michael W and Kanoria, Shaveta and Miller, Melanie J and Aisen, Paul S and Beckett, Laurel A and Conti, Catherine and Diaz, Adam and Flenniken, Derek and Green, Robert C and Harvey, Danielle J and Jack, Clifford R and Jagust, William and Lee, Edward B and Morris, John C and Nho, Kwangsik and Nosheny, Rachel and Okonkwo, Ozioma C and Perrin, Richard J and Petersen, Ronald C and Rivera-Mindt, Monica and Saykin, Andrew J and Shaw, Leslie M and Toga, Arthur W and Tosun, Duygu and Veitch, Dallas P and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {1},
  doi = {10.1002/alz.14321}
}
Kostenlos starten →